"Official medicines" is the best online drugstore.World’s leading meds delivered to your door – and you don’t even need a prescription! Only certified, first class drugs on offer! Buy more and spend less with our great discount system. The meds you need, reliable and hassle free! Top products of top brands.The only pharmacy shop you will ever need! Approved drugs available without prescription. Best deals, unmatched service and shipping. 100% safe! |
| (TI-moe-lahl MAL-ee-ate) |
Betimol, Blocadren, Timoptic-XE, Timoptic, Timoptic Ocudose, Apo-Timol, Apo-Timop, Gen-Timolol, Novo-Timol Ophthalmic Solution, Novo-Timol Tablets, Nu-Timolol, Tim-Ak, |
| Class: Beta-adrenergic blocker |
Action Blocks beta-receptors, which primarily affect heart (slows rate), vascular musculature (decreases blood pressure) and lungs (reduces function). Reduces both elevated and normal IOP via decreasing production of aqueous humor or increasing flow.
Indications Treatment of hypertension, alone or in combination with other agents; eduction of risk of reinfarction post-MI; migraine prophylaxis; treatment of elevated IOP in chronic open-angle glaucoma, ocular hypertension, aphakic glaucoma patients, some patients with secondary glaucoma, and in patients with elevated IOP who need ocular pressure lowering. Unlabeled use(s): Treatment of ventricular arrhythmias and tachycardias, essential tremors, anxiety; management of chronic stable angina pectoris.
Contraindications Hypersensitivity to beta-blockers; greater than first-degree heart block; HF unless secondary to tachyarrhythmia treatable with beta-blockers; overt cardiac failure; sinus bradycardia; cardiogenic shock; bronchial asthma or bronchospasm, including severe COPD.
Hypertension
ADULTS: PO 10 mg bid, titrate to response q 7 days (maximum 60 mg/day).
MI Prophylaxis
ADULTS: PO 10 mg bid.
Migraine Prophylaxis
ADULTS: PO 10 mg bid (maximum 30 mg/day); if no response in 6 weeks then discontinue.
Essential Tremor
ADULTS: PO 10 mg/day.
Glaucoma
ADULTS: Ophthalmic 1 gtt 0.25–0.5% solution in affected eye(s) bid.
Clonidine: May enhance or reverse antihypertensive effect; potentially life-threatening situations may occur, especially on withdrawal. Epinephrine: Initial hypertensive episode followed by bradycardia may occur. Ergot alkaloids: Peripheral ischemia, manifested by cold extremities and possible gangrene, may occur. Insulin: Prolonged hypoglycemia with masking of symptoms may occur. NSAIDs: Some agents may impair antihypertensive effect. Prazosin: Orthostatic hypotension may be increased. Theophyllines: Elimination of theophylline may be reduced. Effects of both drugs may be reduced. Verapamil: Effects of both drugs may be increased.
Lab Test Interferences None well documented.
CV: Hypotension; heart palpitations; bradycardia; heart failure, edema. CNS: Dizziness; depression; lethargy; headache; insomnia; anxiety; tremor; aresthesia. DERM: Increased sensitivity to cold; rash; pruritus; alopecia; sweating. EENT: Transient irritation, burning, tearing and conjunctival edema, blurred vision, light sensitivity (topical use). GI: Abdominal pain; diarrhea; nausea. GU: Impotence; sexual dysfunction; decreased libido; dysuria; urinary retention or frequency; nocturia; increased BUN. HEMA: Decreased Hgb, Hct. META: Alteration of glucose metabolism; masking of hypoglycemia; increased triglycerides, uric acid, potassium. RESP: Wheezing; cough; breathing difficulties, especially in asthmatics or patients with COPD. OTHER: Joint pain; muscle cramps.
Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Abrupt withdrawal: Has been associated with increased angina and MI; gradually decrease dose over 1–2 wk. Anaphylaxis: Deaths have occurred; aggressive therapy may be required. Bronchospasm: Oral and ophthalmic forms may precipitate bronchospasm in susceptible patients. CHF: Administer drug with caution to patients with CHF controlled by digitalis and diuretics. Notify physician at first sign or symptom of CHF or of unexplained respiratory symptoms in any patient. Diabetic patients: Drug may mask signs and symptoms of hypoglycemia, eg, tachycardia, BP changes. Drug may potentiate insulin-induced hypoglycemia. Peripheral vascular disease: Drug may precipitate or aggravate symptoms of arterial insufficiency. Renal/hepatic impairment: Dosage reduction may be required. Thyrotoxicosis: Drug may mask clinical signs, eg, tachycardia, of developing or continuing hyperthyroidism. Abrupt withdrawal may exacerbate symptoms of hyperthyroidism, including thyroid storm.
| PATIENT CARE CONSIDERATIONS |
|
|
||||
Popularity: 1% [?]
RSS feed for comments on this post · TrackBack URI
Leave a reply